메뉴 건너뛰기




Volumn 147, Issue 2, 2011, Pages 340-341

Predictors, moderators and mediators for the effectiveness of pexelizumab treatment in patients undergoing primary coronary revascularization

Author keywords

Mediator; Moderator; Pexelizumab

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PEXELIZUMAB;

EID: 79951953841     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.12.100     Document Type: Article
Times cited : (3)

References (10)
  • 1
    • 0041732120 scopus 로고    scopus 로고
    • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
    • DOI 10.1161/01.CIR.0000087404.53661.F8
    • Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-83. (Pubitemid 37099984)
    • (2003) Circulation , vol.108 , Issue.10 , pp. 1176-1183
    • Mahaffey, K.W.1    Granger, C.B.2    Nicolau, J.C.3    Ruzyllo, W.4    Weaver, W.D.5    Theroux, P.6    Hochman, J.S.7    Filloon, T.G.8    Mojcik, C.F.9    Todaro, T.G.10    Armstrong, P.W.11
  • 2
    • 0042917638 scopus 로고    scopus 로고
    • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
    • DOI 10.1161/01.CIR.0000087447.12918.85
    • Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-90. (Pubitemid 37099985)
    • (2003) Circulation , vol.108 , Issue.10 , pp. 1184-1190
    • Granger, C.B.1    Mahaffey, K.W.2    Weaver, W.D.3    Theroux, P.4    Hochman, J.S.5    Filloon, T.G.6    Rollins, S.7    Todaro, T.G.8    Nicolau, J.C.9    Ruzyllo, W.10    Armstrong, P.W.11
  • 3
    • 33845981823 scopus 로고    scopus 로고
    • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
    • APEX AMI Investigators
    • APEX AMI InvestigatorsArmstrong PW, Granger CB, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
    • (2007) JAMA , vol.297 , pp. 43-51
    • Armstrong, P.W.1    Granger, C.B.2
  • 5
    • 79959361476 scopus 로고    scopus 로고
    • Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials
    • Sep 27 in press, doi:10.1016/j.jtcvs.2010.08.035
    • Smith PK, Shernan SK, Chen JC, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg Sep 27 in press, doi:10.1016/j.jtcvs.2010.08.035.
    • J Thorac Cardiovasc Surg
    • Smith, P.K.1    Shernan, S.K.2    Chen, J.C.3
  • 6
    • 0029029540 scopus 로고
    • The fluid-phase SC5b-9 terminal complement complex binds to the GPIIb/IIIa complex of thrombin-stimulated human blood platelets inhibiting platelet aggregation
    • Røger M, Høgåsen K, Holme PA, et al. The fluid-phase SC5b-9 terminal complement complex binds to the GPIIb/IIIa complex of thrombin-stimulated human blood platelets inhibiting platelet aggregation. Platelet 1995;6:160-8.
    • (1995) Platelet , vol.6 , pp. 160-168
    • Røger, M.1    Høgåsen, K.2    Holme, P.A.3
  • 7
    • 78651422977 scopus 로고    scopus 로고
    • Pexelizumab may be hazardous to those with STsegment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors
    • Lin GM, Chu KM, Han CL. Pexelizumab may be hazardous to those with STsegment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors. Int J Cardiol 2011;146:280-2.
    • (2011) Int J Cardiol , vol.146 , pp. 280-282
    • Lin, G.M.1    Chu, K.M.2    Han, C.L.3
  • 8
    • 0023020183 scopus 로고
    • The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations
    • Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-82.
    • (1986) J Pers Soc Psychol , vol.51 , pp. 1173-1182
    • Baron, R.M.1    Kenny, D.A.2
  • 10
    • 77957884628 scopus 로고    scopus 로고
    • Ethics in the authorship and publishing of scientific articles
    • Shewan LG and Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.
    • (2010) Int J Cardiol , vol.144 , pp. 1-2
    • Shewan, L.G.1    Coats, A.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.